reported the prevalence of hypothyroidism was reduce among men than among women, with a higher prevalence of subclinical than clinical hypothyroidism in both genders [7]

reported the prevalence of hypothyroidism was reduce among men than among women, with a higher prevalence of subclinical than clinical hypothyroidism in both genders [7]. this study was to analyse the prevalence of diagnosed and undiagnosed hypothyroidism, hyperthyroidism (subclinical and medical) and positive thyroid antibodies in the Croatian human population. The results of the study indicated that 17.6% of participants were euthyroid with positive antibodies. The prevalence of medical and subclinical hypothyroidism was 3% and 7.4%, respectively, while the prevalence of clinical and subclinical hyperthyroidism was 0.2% and 1.1%, respectively. Among them, 92.6% subclinical hypothyroid, 93.9% clinical hypothyroid, 83% subclinical hyperthyroid and 71.4% clinical hyperthyroid participants were undiagnosed. Finally, the prevalence of undiagnosed subclinical and medical hypothyroidism in our human population was 6.9% and 2.8%, respectively, while the prevalence of undiagnosed subclinical and clinical hyperthyroidism was 0.9% and 0.1%, respectively. Ladies showed a higher prevalence of thyroid disorders; 1.57 times higher odds of euthyroidism with positive antibodies, 2.1 times higher odds of subclinical hyperthyroidism, 2.37 times higher odds of clinical hypothyroidism and 1.58 times higher odds of subclinical hypothyroidism than men. These results indicate an extremely high proportion of undiagnosed instances, and therefore require purchases inside a prevention programme. 0.05. Statistical analyses were performed using RA language and environment for statistical computing (R Basis for Statistical Computing, Vienna, Austria) [13]. 3. Results The study involved 4402 individuals, 2700 (61.3%) of them ladies and 1702 (38.7%) men, having a Tenofovir (Viread) mean age of 53 and 54, respectively (SD 15.3, 15.8, respectively). Among the participants, 2878 (65.4%) were euthyroid, 773 (17.6%) were euthyroid with positive antibodies, 326 (7.4%) were subclinical hypothyroid, 131 (3%) were clinical hypothyroid, 47 (1.1%) were subclinical hyperthyroid and 7 (0.2%) were clinical hyperthyroid (Table 1). Table 1 includes descriptive statistics for those analysed guidelines: gender, age, weight, thyroid hormones, Tg, positive TgAb and/or TPOAb antibodies, analysis, therapy and thyroid interfering medicines, both in the total sample and within each thyroid function group. Table 2 includes a detailed cross-tabulation overview of thyroid therapy intake and medical thyroid diseases across thyroid function organizations and previously founded diagnoses. Women experienced a higher prevalence of euthyroidism with positive antibodies, subclinical hyperthyroidism, subclinical hypothyroidism and medical hypothyroidism, while males had a higher prevalence of Tenofovir (Viread) euthyroidism (Table 3). Out of the 2700 women in our study, 1049 were 50 years old or more youthful (with mean age 37.3 in the euthyroid, 36 and 34.4 in the clinically and subclinically hyperthyroid, 37 and 35.7 in the clinically and subclinically hypothyroid and 38 in the euthyroid with positive antibodies group). Table 1 Clinical characteristics of study participants. thead th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ /th th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Total /th th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Euthyroid /th th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Euthyroid with Positive Antibodies /th th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Clinical Hyperthyroid /th th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Subclinical Hyperthyroid /th th align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Clinical Hypothyroid /th th align=”center” valign=”middle” style=”border-top:solid Tenofovir (Viread) thin;border-bottom:solid thin” rowspan=”1″ colspan=”1″ Subclinical Hypothyroid /th /thead N (%)44022878 (65.4%)773 (17.6%)7 (0.2%)47 (1.1%)131 (3%)326 (7.4%)Ladies (%)2700 (61.3%)1620 (56.3%)539 (69.7%)3 (42.9%)36 (76.6%)103 (78.6%)231 (70.9%)Age53.4 (15.5)53.2 (15.4)53.6 (15.3)56.71 (15.3)55.7 (17.1)56.72 (14.6)52.02 (17.1)Excess weight77.3 (67.4, 88)78 (67.4, 89.1)76.1 (67.5, 86.1)77.1 (67.8, 87.1)76.3 (70.7, 87.3)73.5 (65.3, 84.9)75.1 (66.5, 86.5)TSH1.6 (1.1, 2.5)1.47 (1.1, 2.1)1.7 (1.2, 2.4)0.04 (0.03, 0.22)0.08 (0.03, 0.16)5.78 (4.2, Emr4 8.5)4.2 (3.9, Tenofovir (Viread) 5.3)fT34.4 (4.2, 4.8)4.4 (4.3, 4.8)4.4 (4.2, 4.8)6.9 (6.1, 7.9)5.3 (4.4, 6.2)3.7 (3.3, 3.9)4.3 (3.9, 4.7)feet412.9 (11.9, 14.1)13.1 (12.1, 14.1)13 (12.1, 14.2)25.2 (22.1, 27.1)15.1 (12.7, 18.3)9.9 (8.9, 10.1)11.9 (10.9, 12.9)Tg9.7 (4.9, 15.9)9.9 (5.4, 15.6)8.9 (2.7, 16.2)6.2 (0.8, 19.9)8.1 (1.7, 21.5)10.2 (4.9, 21.1)10.5 (4.95, 16.8)Positive TPOAb (%)932 (21.1%)0 (0%)679 (87.8%)4 (57.1%)16 (34%)67 (51.1%)127 (39%)Positive TgAb (%)576 (13.1%)0 Tenofovir (Viread) (0%)405 (52.4%)2 (28.6%)12 (25.5%)46 (35.1%)86 (26.4%)Positive TPOAb and/or TgAb1044 (23.7%)0 (0%)773 (100%)4 (57.1%)18 (38.3%)73 (55.7%)132 (40.5%)Previously founded diagnosis (%)151 (3.4%)0 (0%)48 (6.2%)2 (28.6%)8 (17.02%)8 (6.1%)24 (7.4%)Therapy (%)99 (2.3%)0 (0%)35 (4.5%)2 (28.6%)7 (14.9%)7 (5.3%)17 (5.2%)Thyroid interfering medicines41 (0.9%)26 (0.9%)7 (0.9%)0 (0%)0 (0%)1 (0.8%)3 (0.9%) Open in a separate window Data are presented as mean (standard deviation), median (lower quartile, upper quartile) or as frequency (percentage). feet3, free triiodothyronine; feet4, free thyroxine;.